{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:58:36Z","timestamp":1791496716928,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acquired resistance to enzalutamide (Enz) presents a significant challenge in castration-resistant prostate cancer (CRPC), and overcoming this resistance remains an unmet clinical need. Here, we identified cuproptosis, a copper-dependent mechanism of regulated cell death, as a key driver of Enz resistance. Both in vitro and in vivo models demonstrated that pyruvate dehydrogenase E1 alpha subunit (PDHA1) serves as a critical modulator of cuproptosis and Enz sensitivity. Mechanistically, PDHA1 increases intracellular acetyl-CoA, enhancing histone H3K27 acetylation and upregulating solute carrier family 7 member 11 (SLC7A11), which promotes cysteine uptake and glutathione (GSH) synthesis. Elevated GSH chelates intracellular copper, thereby suppressing cuproptosis and reducing Enz efficacy. Targeting PDHA1 significantly restores cuproptosis and sensitizes CRPC cells to Enz treatment. These findings underscore the potential of PDHA1 inhibition to counteract Enz resistance by reactivating cuproptosis, offering a promising therapeutic approach for treating refractory prostate cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-08462-1","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:27:39Z","timestamp":1771842459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PDHA1\u2013acetylation signaling suppresses cuproptosis to attenuate anti-androgen effect in prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Ruilin","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zean","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-3058","authenticated-orcid":false,"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-073X","authenticated-orcid":false,"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-5768","authenticated-orcid":false,"given":"Kaiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"8462_CR1","doi-asserted-by":"crossref","unstructured":"Poutanen M, Hagberg Thulin M, H\u00e4rk\u00f6nen P. Targeting sex steroid biosynthesis for breast and prostate cancer therapy. Nat Rev Cancer. 2023;23:686\u20139.","DOI":"10.1038\/s41568-023-00609-y"},{"key":"8462_CR2","doi-asserted-by":"crossref","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41:1345\u201362.","DOI":"10.1016\/j.ccell.2023.05.016"},{"key":"8462_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354\u201373.","journal-title":"Endocr Rev"},{"key":"8462_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"8462_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med"},{"key":"8462_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease. 2022;13:632.","journal-title":"Cell Death & Disease"},{"key":"8462_CR7","doi-asserted-by":"crossref","unstructured":"Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017;7:a030452.","DOI":"10.1101\/cshperspect.a030452"},{"key":"8462_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020;22:566\u201375.","journal-title":"Neoplasia"},{"key":"8462_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2019","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2019;77:14\u201321.","journal-title":"Eur Urol"},{"key":"8462_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/1535-7163.MCT-21-1002","volume":"22","author":"J Monga","year":"2023","unstructured":"Monga J, Valeriote F, Hwang C, Gadgeel S, Ghosh J. Daclatasvir, an antiviral drug, downregulates tribbles 2 pseudokinase and resensitizes enzalutamide-resistant prostate cancer cells. Mol Cancer Ther. 2023;22:381\u201392.","journal-title":"Mol Cancer Ther"},{"key":"8462_CR11","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang J, Zeng L, Wu N, Liang Y, Jin J, Fan M, et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updat. 2023;70:100985.","journal-title":"Drug Resist Updat"},{"key":"8462_CR12","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.mtbio.2022.100484","volume":"17","author":"J Chen","year":"2022","unstructured":"Chen J, Wang Y, Han L, Wang R, Gong C, Yang G, et al. A ferroptosis-inducing biomimetic nanocomposite for the treatment of drug-resistant prostate cancer. Mater Today Bio. 2022;17:100484.","journal-title":"Mater Today Bio"},{"key":"8462_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40364-025-00822-x","volume":"13","author":"F-H Ji","year":"2025","unstructured":"Ji F-H, Qian Y-H, Guo X-C, Liao H-H, Huang J-C, Xu Z-H, et al. Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer. Biomark Res. 2025;13:109.","journal-title":"Biomark Res"},{"key":"8462_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"8462_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","volume":"35","author":"A Gupte","year":"2009","unstructured":"Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35:32\u201346.","journal-title":"Cancer Treat Rev"},{"key":"8462_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/01.ede.0000209454.41466.b7","volume":"17","author":"N Leone","year":"2006","unstructured":"Leone N, Courbon D, Ducimetiere P, Zureik M. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology. 2006;17:308\u201314.","journal-title":"Epidemiology"},{"key":"8462_CR17","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1158\/0008-5472.CAN-13-3527","volume":"74","author":"R Safi","year":"2014","unstructured":"Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014;74:5819\u201331.","journal-title":"Cancer Res"},{"key":"8462_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12967-022-03630-1","volume":"20","author":"C Yan","year":"2022","unstructured":"Yan C, Niu Y, Ma L, Tian L, Ma J. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med. 2022;20:452.","journal-title":"J Transl Med"},{"key":"8462_CR19","doi-asserted-by":"publisher","first-page":"106831","DOI":"10.1016\/j.compbiomed.2023.106831","volume":"158","author":"X Xiaona","year":"2023","unstructured":"Xiaona X, Liu Q, Zhou X, Liang R, Yang S, Xu M, et al. Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in lung adenocarcinoma. Comput Biol Med. 2023;158:106831.","journal-title":"Comput Biol Med"},{"key":"8462_CR20","doi-asserted-by":"publisher","first-page":"1056932","DOI":"10.3389\/fimmu.2022.1056932","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Qin D, Tao Z, Wang B, Xie Y, Wang Y, et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol. 2022;13:1056932.","journal-title":"Front Immunol"},{"key":"8462_CR21","doi-asserted-by":"publisher","first-page":"e2401396","DOI":"10.1002\/advs.202401396","volume":"11","author":"X Gao","year":"2024","unstructured":"Gao X, Zhao H, Liu J, Wang M, Dai Z, Hao W, et al. Enzalutamide sensitizes castration-resistant prostate cancer to copper-mediated cell death. Adv Sci. 2024;11:e2401396.","journal-title":"Adv Sci"},{"key":"8462_CR22","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1038\/s41467-022-35199-0","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Long Q, Wu H, Zhou Y, Duan L, Yuan H, et al. Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation. Nat Commun. 2022;13:7414.","journal-title":"Nat Commun"},{"key":"8462_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cell.2014.04.046","volume":"158","author":"G Sutendra","year":"2014","unstructured":"Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 2014;158:84\u201397.","journal-title":"Cell"},{"key":"8462_CR24","doi-asserted-by":"publisher","first-page":"e2308422","DOI":"10.1002\/advs.202308422","volume":"11","author":"L Yuan","year":"2024","unstructured":"Yuan L, Jiang H, Jia Y, Liao Y, Shao C, Zhou Y, et al. Fatty acid oxidation supports lymph node metastasis of cervical cancer via Acetyl-CoA-mediated stemness. Adv Sci. 2024;11:e2308422.","journal-title":"Adv Sci"},{"key":"8462_CR25","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/0008-5472.CAN-20-0233","volume":"80","author":"S Xu","year":"2020","unstructured":"Xu S, Fan L, Jeon H-Y, Zhang F, Cui X, Mickle MB, et al. p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer. Cancer Res. 2020;80:3074\u201387.","journal-title":"Cancer Res"},{"key":"8462_CR26","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/s41467-023-38887-7","volume":"14","author":"T Nguyen","year":"2023","unstructured":"Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, et al. Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat Commun. 2023;14:3357.","journal-title":"Nat Commun"},{"key":"8462_CR27","doi-asserted-by":"publisher","first-page":"eado8333","DOI":"10.1126\/scitranslmed.ado8333","volume":"16","author":"Z Wang","year":"2024","unstructured":"Wang Z, Di Y, Wen X, Liu Y, Ye L, Zhang X, et al. NIT2 dampens BRD1 phase separation and restrains oxidative phosphorylation to enhance chemosensitivity in gastric cancer. Sci Transl Med. 2024;16:eado8333.","journal-title":"Sci Transl Med"},{"key":"8462_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-020-1536-x","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang H, Fu C, Du J, Wang H, He R, Yin X, et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. 2020;39:29.","journal-title":"J Exp Clin Cancer Res"},{"key":"8462_CR29","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, Ding D, Wang L, Pang J, et al. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res. 2023;83:3192\u2013204.","journal-title":"Cancer Res"},{"key":"8462_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7:286.","journal-title":"Signal Transduct Target Ther"},{"key":"8462_CR31","doi-asserted-by":"publisher","first-page":"18285","DOI":"10.1073\/pnas.1904610116","volume":"116","author":"CY-S Chung","year":"2019","unstructured":"Chung CY-S, Posimo JM, Lee S, Tsang T, Davis JM, Brady DC, et al. Activity-based ratiometric FRET probe reveals oncogene-driven changes in labile copper pools induced by altered glutathione metabolism. Proceedings of the National Academy of Sciences of the United States of America. 2019;116:18285\u201394.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8462_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mam.2008.05.005","volume":"30","author":"SC Lu","year":"2009","unstructured":"Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42\u201359.","journal-title":"Mol Aspects Med"},{"key":"8462_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","volume":"21","author":"F Pietrocola","year":"2015","unstructured":"Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metabolism. 2015;21:805\u201321.","journal-title":"Cell Metabolism"},{"key":"8462_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cmet.2015.02.002","volume":"21","author":"A Moussaieff","year":"2015","unstructured":"Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metabolism. 2015;21:392\u2013402.","journal-title":"Cell Metabolism"},{"key":"8462_CR35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00109-011-0785-8","volume":"89","author":"Z Zachar","year":"2011","unstructured":"Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011;89:1137\u201348.","journal-title":"J Mol Med (Berl)"},{"key":"8462_CR36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/0008-5472.CAN-23-0555","volume":"84","author":"D Awad","year":"2024","unstructured":"Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, et al. Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. Cancer Res. 2024;84:703\u201324.","journal-title":"Cancer Res"},{"key":"8462_CR37","doi-asserted-by":"publisher","first-page":"115792","DOI":"10.1016\/j.celrep.2025.115792","volume":"44","author":"C Lin","year":"2025","unstructured":"Lin C, Pulliam TL, Han JJ, Xu J, Recio CV, Wilkenfeld SR, et al. Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025;44:115792.","journal-title":"Cell Rep"},{"key":"8462_CR38","doi-asserted-by":"publisher","first-page":"9570","DOI":"10.1038\/s41598-024-57303-8","volume":"14","author":"L Yang","year":"2024","unstructured":"Yang L, Tang Y, Zhang Y, Wang Y, Jiang P, Liu F, et al. Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer. Sci Rep. 2024;14:9570.","journal-title":"Sci Rep"},{"key":"8462_CR39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.csbj.2024.02.016","volume":"23","author":"L Xu","year":"2024","unstructured":"Xu L, Yang L, Zhang D, Wu Y, Shan J, Zhu H, et al. Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis. Comput Struct Biotechnol J. 2024;23:1201\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"8462_CR40","doi-asserted-by":"publisher","first-page":"1344755","DOI":"10.3389\/fphar.2024.1344755","volume":"15","author":"H Lv","year":"2024","unstructured":"Lv H, Liu L, He Y, Yang K, Fu Y, Bao Y. Role of hippo pathway and cuproptosis-related genes in immune infiltration and prognosis of skin cutaneous melanoma. Front Pharmacol. 2024;15:1344755.","journal-title":"Front Pharmacol"},{"key":"8462_CR41","doi-asserted-by":"publisher","first-page":"e23143","DOI":"10.1096\/fj.202300474R","volume":"37","author":"X Wang","year":"2023","unstructured":"Wang X, Jia J-H, Zhang M, Meng Q-S, Yan B-W, Ma Z-Y, et al. Adrenomedullin\/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis. FASEB J. 2023;37:e23143.","journal-title":"FASEB J"},{"key":"8462_CR42","doi-asserted-by":"publisher","first-page":"e23145","DOI":"10.1096\/fj.202300980R","volume":"37","author":"H Wen","year":"2023","unstructured":"Wen H, Qu C, Wang Z, Gao H, Liu W, Wang H, et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT\/mTOR pathway in prostate cancer. FASEB J. 2023;37:e23145.","journal-title":"FASEB J"},{"key":"8462_CR43","doi-asserted-by":"crossref","unstructured":"Li P, Sun Q, Bai S, Wang H, Zhao L. Combination of the cuproptosis inducer disulfiram and anti\u2011PD\u2011L1 abolishes NSCLC resistance by ATP7B to regulate the HIF\u20111 signaling pathway. Int J Mol Med. 2024;53:5345.","DOI":"10.3892\/ijmm.2023.5343"},{"key":"8462_CR44","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/med.22025","volume":"44","author":"J Wu","year":"2024","unstructured":"Wu J, He J, Liu Z, Zhu X, Li Z, Chen A, et al. Cuproptosis: mechanism, role, and advances in urological malignancies. Med Res Rev. 2024;44:1662\u201382.","journal-title":"Med Res Rev"},{"key":"8462_CR45","doi-asserted-by":"crossref","unstructured":"Kennedy L, Sandhu JK, Harper M-E, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10:1429.","DOI":"10.3390\/biom10101429"},{"key":"8462_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/toxics3010020","volume":"3","author":"FM Rubino","year":"2015","unstructured":"Rubino FM. Toxicity of glutathione-binding metals: a review of targets and mechanisms. Toxics. 2015;3:20\u201362.","journal-title":"Toxics"},{"key":"8462_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599\u2013620.","journal-title":"Protein Cell"},{"key":"8462_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-023-02720-2","volume":"42","author":"W Wang","year":"2023","unstructured":"Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res. 2023;42:142.","journal-title":"J Exp Clin Cancer Res"},{"key":"8462_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-023-02764-4","volume":"42","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Chen X, Yao K, Zhang Y, He H, Huang H, et al. TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination. J Exp Clin Cancer Res. 2023;42:195.","journal-title":"J Exp Clin Cancer Res"},{"key":"8462_CR50","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1002\/ctm2.191","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Wang Q, Peng S, Yao K, Chen J, Tao Y, et al. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. Clin Transl Med. 2020;10:e191.","journal-title":"Clin Transl Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08462-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08462-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08462-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:03:21Z","timestamp":1772798601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08462-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8462"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08462-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University (SYSU-IACUC-2021-000041) and conducted in accordance with the university\u2019s guidelines for Animal Care and Use. The use of human tissues was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital (SYSEC-KY-KS-2020-201).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"243"}}